[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
Schadendorf, D., Van Akkooi, A.C.J., Berking, C., et al. (2018) Melano-ma. The Lancet, 392, 971-984.
https://doi.org/10.1016/S0140-6736(18)31559-9
|
[3]
|
Zaremba, A., Zimmer, L., Griewank, K.G., et al. (2020) Im-munotherapy Beim Malignant Melanoma. Der Internist, 61, 669-675. https://doi.org/10.1007/s00108-020-00812-1
|
[4]
|
Bennet, W.H. (1899) Some Peculiarities in the Behaviour of Certain Malignant and Innocent Growths. The Lancet, 153, 3-7. https://doi.org/10.1016/S0140-6736(01)78943-X
|
[5]
|
Petrova, V., Arkhypov, I., Weber, R., et al. (2020) Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. International Journal of Molecular Sciences, 21, Article 2367. https://doi.org/10.3390/ijms21072367
|
[6]
|
Curran, M.A., Montalvo, W., Yagita, H. and Allison, J.P. (2010) PD-1 and CTLA-4 Combination Blockade Expands Infiltrating T Cells and Reduces Regulatory T and Myeloid Cells within B16 Melanoma Tumors. Proceedings of the National Academy of Sciences of the United States of America, 107, 4275-4280.
https://doi.org/10.1073/pnas.0915174107
|
[7]
|
Goldrath, A.W. and Bevan, M.J. (1999) Selecting and Maintaining a Diverse T-Cell Repertoire. Nature, 402, 255-262.
https://doi.org/10.1038/46218
|
[8]
|
Fife, B.T. and Bluestone, J.A. (2008) Control of Peripheral T-Cell Tolerance and Autoimmunity via the CTLA-4 and PD-1 Pathways. Immunological Reviews, 224, 166-182. https://doi.org/10.1111/j.1600-065X.2008.00662.x
|
[9]
|
Walunas, T.L., Lenschow, D.J., Bakker, C.Y., et al. (1994) CTLA-4 Can Function as a Negative Regulator of T Cell Activation. Immunity, 1, 405-413. https://doi.org/10.1016/1074-7613(94)90071-X
|
[10]
|
Krummel, M.F. and Allison, J.P. (1995) CD28 and CTLA-4 Have Opposing Effects on the Response of T Cells to Stimulation. Journal of Experimental Medicine, 182, 459-465. https://doi.org/10.1084/jem.182.2.459
|
[11]
|
Brunner, M.C., Chambers, C.A., Chan, F.K., et al. (1999) CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation. The Journal of Immunology, 162, 5813-5820. https://doi.org/10.4049/jimmunol.162.10.5813
|
[12]
|
Leach, D.R., Krummel, M.F. and Allison, J.P. (1996) En-hancement of Antitumor Immunity by CTLA-4 Blockade. Science, 271, 1734-1736. https://doi.org/10.1126/science.271.5256.1734
|
[13]
|
Van Elsas, A., Hurwitz, A.A. and Allison, J.P. (1999)
Combi-nation Immunotherapy of B16 Melanoma Using Anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4)
and Granulocyte/Macrophage Colony-Stimulating Factor
(GM-CSF)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by
Autoimmune Depigmentation. Journal of Experimental
Medicine, 190, 355-366. https://doi.org/10.1084/jem.190.3.355
|
[14]
|
Koga, N., Suzuki, J., Kosuge, H., et al. (2004) Blockade of the Interac-tion between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 2057-2062.
https://doi.org/10.1161/01.ATV.0000145015.23656.e4
|
[15]
|
Hirano, F., Kaneko, K., Tamura, H., et al. (2005) Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity. Cancer Research, 6, 1089-1096. https://doi.org/10.1158/0008-5472.1089.65.3
|
[16]
|
Day, C.L., Kaufmann, D.E., Kiepiela, P., et al. (2006) PD-1 Expression on HIV-Specific T Cells Is Associated with T-Cell Exhaustion and Disease Progression. Nature, 443, 350-354. https://doi.org/10.1038/nature05115
|
[17]
|
Keir, M.E., Butte, M.J., Freeman, G.J., et al. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. https://doi.org/10.1146/annurev.immunol.26.021607.090331
|
[18]
|
Parry, R.V., Chemnitz, J.M., Frauwirth, K.A., et al. (2005) CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. Molecular and Cellular Bi-ology, 25, 9543-9553.
https://doi.org/10.1128/MCB.25.21.9543-9553.2005
|
[19]
|
Krummel, M.F. and Allison, J.P. (1996) CTLA-4 En-gagement Inhibits IL-2 Accumulation and Cell Cycle Progression Upon Activation of Resting T Cells. Journal of Ex-perimental Medicine, 183, 2533-2540.
https://doi.org/10.1084/jem.183.6.2533
|
[20]
|
Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J., Green, J.M., Thompson, C.B., et al. (1994) CTLA-4 Can Function as a Negative Regulator of T Cell Activation. Immunity, 1, 405-413.
https://doi.org/10.1016/1074-7613(94)90071-X
|
[21]
|
Alegre, M.L., Noel, P.J., Eisfelder, B.J., Chuang, E., Clark, M.R., Reiner, S.L. and Thompson, C.B. (1996) Regulation of Surface and Intracellular Expression of CTLA4 on Mouse T Cells. The Journal of Immunology, 157, 4762-4770.
https://doi.org/10.4049/jimmunol.157.11.4762
|
[22]
|
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T.W., et al. (2000) Immunologic Self-Tolerance Maintained by CD25+CD4+ Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte-Associated Antigen 4. Journal of Experimental Medicine, 192, 303-310. https://doi.org/10.1084/jem.192.2.303
|
[23]
|
Sansom, D.M. (2000) CD28, CTLA-4 and Their Ligands: Who Does What and to Whom? Immunology, 101, 169-177.
https://doi.org/10.1046/j.1365-2567.2000.00121.x
|
[24]
|
Linsley, P.S., Bradshaw, J., Greene, J., Peach, R., Bennett, K.L. and Mittler, R.S. (1996) Intracellular Trafficking of CTLA-4 and Focal Localization towards Sites of TCR Engage-ment. Immunity, 4, 535-543.
https://doi.org/10.1016/S1074-7613(00)80480-X
|
[25]
|
Egen, J.G. and Allison, J.P. (2002) Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength. Immunity, 16, 23-35. https://doi.org/10.1016/S1074-7613(01)00259-X
|
[26]
|
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., et al. (2001) Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice. Science, 291, 319-322.
https://doi.org/10.1126/science.291.5502.319
|
[27]
|
Qureshi, O.S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E.M., Baker, J., et al. (2011) Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4. Science, 332, 600-603. https://doi.org/10.1126/science.1202947
|
[28]
|
Hodi, F.S., O’day, S.J., Mcdermott, D.F., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Mela-noma. The New England Journal of Medicine, 363, 711-723.
|
[29]
|
Cybulska-Stopa, B., et al. (2020) Efcacy of Ipili-mumab after Anti-PD-1 Therapy in Sequential Treatment of Metastatic Melanoma Patients-Real World Evidence. Ad-vances in Medical Sciences, 65, 316-323.
https://doi.org/10.1016/j.advms.2020.05.005
|
[30]
|
Shrikant, P., Khoruts, A. and Mescher, M.F. (1999) CTLA-4 Blockade Reverses CD8+T Cell Tolerance to Tumor by a CD4+ T Cell- and IL-2-Dependent Mechanism. Immunity, 11, 483-493.
https://doi.org/10.1016/S1074-7613(00)80123-5
|
[31]
|
Hodi, F.S., O’Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. The New England Journal of Medicine, 363, 711-723. https://doi.org/10.1056/NEJMoa1003466
|
[32]
|
Namikawa, K., Kiyohara, Y., Takenouchi, T., Uhara, H., Uchi, H., Yoshikawa, S., Takatsuka, S., Koga, H., Wada, N., Minami, H., et al. (2018) Efficacy and Safety of Nivolumab in Com-bination with Ipilimumab in Japanese Patients with Advanced Melanoma: An Open-Label, Single-Arm, Multicentre Phase II Study. European Journal of Cancer, 105, 114-126. https://doi.org/10.1016/j.ejca.2018.09.025
|
[33]
|
McDermott, D., Haanen, J., Chen, T.T., Lorigan, P. and O’Day, S. (2013) Efficacy and Safety of Ipilimumab in Metastatic Melanoma Patients Surviving More than 2 Years Following Treatment in a Phase III Trial (MDX010-20). Annals of Oncology, 24, 2694-2698. https://doi.org/10.1093/annonc/mdt291
|
[34]
|
Zou, W. and Chen, L. (2008) Inhibitory B7-Family Molecules in the Tumour Microenvironment. Nature Reviews Immunology, 8, 467-477. https://doi.org/10.1038/nri2326
|
[35]
|
Tsutsumida, A., et al. (2019) Japanese Real-World Study of Sequential Nivolumab and Ipilimumab Treament in Melanoma. The Journal of Dermatology, 46, 947-955. https://doi.org/10.1111/1346-8138.15073
|
[36]
|
Fujisawa, Y., et al. (2018) Retrospective Study of Advanced Mela-noma Patients Treated with Ipilimumab after Nivolumab: Analysis of 60 Japanese Patients. Journal of Dermatological Science, 89, 60-66.
https://doi.org/10.1016/j.jdermsci.2017.10.009
|
[37]
|
Muto, Y., et al. (2019) Investigation of Clinical Factors Asso-ciated with Longer Overall Survival in Advanced Melanoma Patients Treated with Sequential Ipilimumab. The Journal of Dermatology, 46, 498-506.
https://doi.org/10.1111/1346-8138.14865
|
[38]
|
Baron, K., et al. (2020) Comparative Effectiveness of Second-Line Ipilimumab vs Nivolumab in Combination with Ipilimumab in Patients with Advanced Melanoma Who Received Front-line Anti-PD-1 Antibodies. Journal of Oncology Pharmacy Practice, 27, 555-559. https://doi.org/10.1177/1078155220924719
|
[39]
|
Mehmi, I. and Hill, J. (2018) Ipilimumab with Anti PD-1 (Nivovlumab or Pembrolizumab) after Progression on First Line Anti-PD-1 Therapy for Advanced Melanoma. Journal of Clinical Oncology, 36, e21552.
https://doi.org/10.1200/JCO.2018.36.15_suppl.e21552
|
[40]
|
Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., Patt, D., Chen, T.T., Berman, D.M. and Wolchok, J.D. (2015) Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 33, 1889-1894.
https://doi.org/10.1200/JCO.2014.56.2736
|
[41]
|
Ascierto, P.A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chi-arionSileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., et al. (2017) Ipilimumab 10 mg/kg versus Ipilimumab 3 mg/kg in Patients with Unresectable or Metastatic Melanoma: A Randomised, Doubleblind, Multicentre, Phase 3 Trial. The Lancet Oncology, 18, 611-622. https://doi.org/10.1016/S1470-2045(17)30231-0
|
[42]
|
Institute, N.C. (2017) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
https://ctep.cancer.gov/protocolDevelopment/
electronic_applications/docs/CTCAE_v5_Quick_Reference
_5x7.pdf
|
[43]
|
Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) Nivolumab in Previously Untreated Melanoma without BRAF Mutation. The New England Journal of Medicine, 372, 320-330. https://doi.org/10.1056/NEJMoa1412082
|
[44]
|
Sullivan, R.J., Hamid, O., Gonzalez, R., Infante, J.R., Patel, M.R., Hodi, F.S., Lewis, K.D., Tawbi, H.A., Hernandez, G., Wongchenko, M.J., et al. (2019) Atezolizumab plus Cobimetinib and Vemurafenib in BRAF-Mutated Melanoma Patients. Nature Medicine, 25, 929-935.
|
[45]
|
Ascierto, P.A., Long, G.V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A.M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., et al. (2019) Survival Outcomes in Patients with Previously Untreated Brafwild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-Up of a Randomized Phase 3 Trial. JAMA Oncology, 5, 187-194. https://doi.org/10.1001/jamaoncol.2018.4514
|
[46]
|
Michot, J.M., Bigenwald, C., Champiat, S., et al. (2016) Immune-Related Adverse Events with Immune Checkpoint Blockade: A Comprehensive Review. Euro-pean Journal of Cancer, 54, 139-148.
https://doi.org/10.1016/j.ejca.2015.11.016
|
[47]
|
Marrone, K.A., Ying, W. and Naidoo, J. (2016) Immunerelated Adverse Events from Immune Checkpoint Inhibitors. Clinical Pharmacology & Therapeutics, 100, 242-251. https://doi.org/10.1002/cpt.394
|
[48]
|
Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., et al. (2017) Overall Surviv-al with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 377, 1345-1356.
https://doi.org/10.1056/NEJMoa1709684
|
[49]
|
Antonia, S.J., Lopez-Martin, J.A., Bendell, J., et al. (2016) Nivolumab Alone and Nivolumab plus Ipilimumab in Recurrent Small-Cell Lung Cancer (CheckMate032): A Multicentre, Open-Label, Phase 1/2 Trial. The Lancet Oncology, 17, 883-895. https://doi.org/10.1016/S1470-2045(16)30098-5
|
[50]
|
Weber, J.S., Hodi, F.S., Wolchok, J.D., et al. (2017) Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients with Advanced Melanoma. Journal of Clinical On-cology, 35, 785-792.
https://doi.org/10.1200/JCO.2015.66.1389
|
[51]
|
Larkin, J., Lao, C.D., Urba, W.J., et al. (2015) Efficacy and Safety of Nivolumab in Patients with BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. JAMA Oncology, 1, 433-440.
https://doi.org/10.1001/jamaoncol.2015.1184
|